Chen et al. suggested that the TPMT gene polymorphism in Chinese SLE patients had a low sensitivity to predict leukopenia, resulting in a limited clinical value; therefore, they recommended that the AZA dose should be adjusted by monitoring the enzyme activity of TPMT (Chen et al., 2014). This evidence concerns the gene TPMT and systemic lupus erythematosus.